NNC 0165 1562Alternative Names: NC01651562; NNC-01651562
Latest Information Update: 23 Feb 2017
At a glance
- Originator Novo Nordisk
- Class Obesity therapies
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Obesity
Most Recent Events
- 01 Feb 2017 Novo Nordisk completes a phase I trial for Obesity in USA (NCT02568306)
- 02 Oct 2015 Novo Nordisk plans a phase I trial for Obesity in USA (NCT02568306)